alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
I 

118TH CONGRESS 

2D SESSION H. R. 7615 

To allow States to elect to observe daylight savings time for the duration 

of the year, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 11, 2024 

Ms. MALOY introduced the following bill; which was referred to the Committee 

on Energy and Commerce 

A BILL 

To allow States to elect to observe daylight savings time 

for the duration of the year, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Daylight Act’’. 

5 SEC. 2. OPTIONAL YEAR-LONG APPLICATION OF DAYLIGHT 

6 SAVINGS TIME. 

7 Section 3(a) of the Uniform Time Act of 1966 (15 

8 U.S.C. 260a) is amended— 

9 (1) by inserting ‘‘or may by law apply the ad10 vancement of time described in this section for the 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•HR 7615 IH

1 duration of the year,’’ after ‘‘may by law exempt 

2 itself from the provisions of this subsection providing 

3 for the advancement of time,’’; 

4 (2) by striking ‘‘the standard time otherwise 

5 applicable during that period’’ and inserting ‘‘the 

6 same standard time’’; 

7 (3) by striking ‘‘may by law exempt either the 

8 entire State as provided in (1) or’’ and inserting ‘‘, 

9 by law, may apply either standard time provided for 

10 in paragraph (1) to the entire State,’’; and 

11 (4) by inserting ‘‘, or may apply the advance12 ment of time for the duration of the year to the en13 tire area of the State lying within any time zone’’ 

14 before the period at the end. 

Æ 


ssavage on LAPJG3WLY3PROD with BILLS
#### Aida Bahr *v.*The Prudential Insurance Company of America

*Donald C. Cousins,*in support of the petition.

*Edward J. Holahan, Jr.,*in opposition.

Submitted March 13

decided April 1, 1969

The petition by the plaintiff for certification for appeal from the Appellate Division of the Circuit Court is denied.
# C_2016364EN.01005102.xml

| 3.10.2016 | EN | Official Journal of the European Union | C 364/51 |
| --- | --- | --- | --- |

3.10.2016

EN

Official Journal of the European Union

C 364/51

---

Order of the Civil Service Tribunal (2nd Chamber) of 20 July 2016 — Belis v Commission

(Case F-108/14) (1)

((Civil service - Officials - Pensions - Transfer of national pension rights - Proposal concerning additional pensionable years - Act not having an adverse effect - Inadmissibility of the action - Application for a decision not going to the merits of the case - Article 83 of the Rules of Procedure))

(2016/C 364/66)

Language of the case: French

Parties

Applicant: Claudio Belis (Ispra, Italy) (represented by: S. Orlandi, lawyer)

Defendant: European Commission (represented initially by J. Currall and G. Gattinara, and subsequently by G. Gattinara and F. Simonetti, acting as Agents)

Re:

Application for annulment of the decision crediting the applicant’s pension rights in relation to the transfer of those rights to the European Union pension scheme, pursuant to the new GIP relating to Articles 11 and 12 of Annex VIII to the Staff Regulations.

Operative part of the order

| 1. | The action is dismissed as inadmissible. |
| --- | --- |

1.

The action is dismissed as inadmissible.

| 2. | Mr Claudio Belis shall bear his own costs and pay the costs incurred by the European Commission. |
| --- | --- |

2.

Mr Claudio Belis shall bear his own costs and pay the costs incurred by the European Commission.

---

(1)  OJ C 26, 26/1/2015, p. 46.

---
§ 524.981d Fluocinolone and dimethyl sulfoxide solution. ( a ) *Specifications.* Each milliliter of solution contains 0.01 percent fluocinolone acetonide and 20 percent dimethyl sulfoxide.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* Instill 1 to 2 milliliters into each anal sac following expression of anal sac contents.
( 2 ) *Indications for use.* For the relief of impaction commonly present in apparently normal anal sacs, for the reversal of inflammatory changes associated with abnormal anal sacs, and to counteract the offensive odor of anal sac secretions.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 10969, Feb. 27, 2014]
WARNING: THE EDGAR SYSTEM ENCOUNTERED ERROR(S) WHILE PROCESSING THIS SCHEDULE.

<TABLE> <S> <C>

<ARTICLE> 5
<CURRENCY> 
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          OCT-31-1997
<PERIOD-START>                             FEB-01-1997
<PERIOD-END>                               APR-30-1997
<EXCHANGE-RATE>                                      1
<CASH>                                       1,793,620
<SECURITIES>                                         0
<RECEIVABLES>                                2,550,732
<ALLOWANCES>                                    80,000
<INVENTORY>                                  8,053,662
<CURRENT-ASSETS>                            12,900,433
<PP&E>                                      10,307,908
<DEPRECIATION>                               5,657,874
<TOTAL-ASSETS>                              18,320,806
<CURRENT-LIABILITIES>                        4,902,371
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        81,153
<OTHER-SE>                                  10,610,361
<TOTAL-LIABILITY-AND-EQUITY>                18,320,806
<SALES>                                      3,574,015
<TOTAL-REVENUES>                             5,115,743
<CGS>                                        2,463,524
<TOTAL-COSTS>                                9,389,409
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                            (4,273,666)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (4,273,666)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (4,273,666)
<EPS-PRIMARY>                                    (.54)
<EPS-DILUTED>                                    (.54)
        

</TABLE>
### Ground water for irrigation in part of the Fort Hall Indian Reservation, Idaho

By: Sam W. WestChabot Kilburn

                            https://doi.org/10.3133/wsp1576D

#### Links

-                                                                                                                             Document:                                                                                                                                                                                                                                                  **Report**                                                                                                     (pdf)                                                                                                                                     
- Plates:                               - **Plate 1**                            (pdf)
  - **Plate 2**                            (pdf)
  - **Plate 3**                            (pdf) 
- NGMDB Index Page:  **National Geologic Map Database Index Page**                            (html)
- Download citation as:  RIS                         |                         Dublin                            Core

#### Abstract

No abstract available.

#### Study Area

Part or all of this report is presented in Portable Document Format                        (PDF). For best results viewing and printing PDF documents, it is recommended that you download                        the documents to your computer and open them with Adobe Reader. PDF documents opened from your                        browser may not display or print as intended. Download the latest version of Adobe Reader, free of charge. More information                        about viewing, downloading, and printing report files can be found at the common download problems FAQ.
Editorial Note on Part 73
Editorial Note: Nomenclature changes to part 73 appear at 66 FR 66742, Dec. 27, 2001.

§ 73.2125 Potassium sodium copper chlorophyllin (chlorophyllin-copper complex). ( a ) *Identity and specifications.* The color additive potassium sodium copper chlorophyllin shall conform in identity and specifications to the requirements of § 73.1125(a)(1) and (b).
( b ) *Uses and restrictions.* Potassium sodium copper chlorophyllin may be safely used for coloring dentifrices that are cosmetics subject to the following conditions: ( 1 ) It shall not be used at a level in excess of 0.1 percent.
( 2 ) It may be used only in combination with the following substances: Water. Glycerin. Sodium carboxymethylcellulose. Tetrasodium pyrophosphate. Sorbitol. Magnesium phosphate, tribasic. Calcium carbonate. Calcium phosphate, dibasic. Sodium *N*-lauroyl sarcosinate. Artificial sweeteners that are generally recognized as safe or that are authorized under subchapter B of this chapter. Flavors that are generally recognized as safe or that are authorized under subchapter B of this chapter. Preservatives that are generally recognized as safe or that are authorized under subchapter B of this chapter.
( c ) *Labeling.* The label of the color additive shall conform to the requirements of § 70.25 of this chapter.
( d ) *Exemption from certification.* Certification of this color additive is not necessary for the protection of the public health and therefore batches thereof are exempt from the certification requirements of section 721(c) of the act.
Exhibit








Exhibit 10.1




Housing Allowance for President and Chief Executive Officer


On February 24, 2017, the Compensation and Personnel Committee (the “Committee”) of the Board of Directors of Vectrus, Inc. (the “Company”) approved a housing allowance for Charles L. Prow, the Company’s President and Chief Executive Officer, in the amount of $3,000 per month.  Mr. Prow, who was hired in December 2016 and works primarily at the Company’s Reston, Virginia office, is expected to spend a substantial amount of time in Colorado Springs, Colorado (the location of the Company’s headquarters).  The Committee approved the housing allowance, which will not be grossed up for taxes, following the Company’s cost analysis that indicated that the allowance would be less expensive than estimated hotel costs for his visits to Colorado Springs.  The Company previously paid a total of $2,827 for a short-term apartment rental in Colorado Springs in 2017.
§ 582.6757 Sodium gluconate. ( a ) *Product.* Sodium gluconate.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
§ 640.33 Testing the blood. ( a ) Blood from which plasma is separated shall be tested as prescribed in § 610.40 of this chapter and § 640.5 (b) and (c).
( b ) Manufacturers of Plasma collected by plasmapheresis shall have testing and recordkeeping responsibilities equivalent to those prescribed in §§ 640.71 and 640.72.
[42 FR 59878, Nov. 22, 1977, as amended at 44 FR 17658, Mar. 23, 1979; 50 FR 4139, Jan. 29, 1985; 53 FR 117, Jan. 5, 1988; 66 FR 31165, June 11, 2001; 80 FR 29905, May 22, 2015]
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 09-7549

MARCO BATES,

Petitioner - Appellant,

v.

MCKITHER BODISON, Warden of Lieber Correctional Institution,

Respondent - Appellee.

Appeal from the United States District Court for the District of 

South Carolina, at Rock Hill. Henry M. Herlong, Jr., Senior 

District Judge. (0:08-cv-02273-HMH)

Submitted: December 31, 2009 Decided: March 1, 2010

Before MOTZ, KING, and AGEE, Circuit Judges.

Dismissed by unpublished per curiam opinion.

Marco Bates, Appellant Pro Se. William Edgar Salter, III, 

Assistant Attorney General, Donald John Zelenka, Deputy 

Assistant Attorney General, Columbia, South Carolina, for 

Appellee.

Unpublished opinions are not binding precedent in this circuit.
2

PER CURIAM:

Marco Bates seeks to appeal the district court’s order 

accepting the recommendation of the magistrate judge and denying 

relief on his 28 U.S.C. § 2254 (2006) petition. The order is 

not appealable unless a circuit justice or judge issues a 

certificate of appealability. See 28 U.S.C. § 2253(c)(1) 

(2006). A certificate of appealability will not issue absent “a 

substantial showing of the denial of a constitutional right.” 

28 U.S.C. § 2253(c)(2) (2006). A prisoner satisfies this 

standard by demonstrating that reasonable jurists would find 

that any assessment of the constitutional claims by the district 

court is debatable or wrong and that any dispositive procedural 

ruling by the district court is likewise debatable. See MillerEl v. Cockrell, 537 U.S. 322, 336-38 (2003); Slack v. McDaniel, 

529 U.S. 473, 484 (2000); Rose v. Lee, 252 F.3d 676, 683-84 (4th 

Cir. 2001). We have independently reviewed the record and 

conclude that Bates has not made the requisite showing. 

Accordingly, we deny a certificate of appealability and dismiss 

the appeal. We dispense with oral argument because the facts 

and legal contentions are adequately presented in the materials 

before the court and argument would not aid the decisional 

process. 

DISMISSED
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
financial statements at December 31, 1996 Audited and is qualified in its
entirety by reference to such financial statements.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-END>                               DEC-31-1996
<CASH>                                         444,661
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                               463,063
<PP&E>                                          39,822
<DEPRECIATION>                                  15,835
<TOTAL-ASSETS>                                 488,839
<CURRENT-LIABILITIES>                          190,748
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        94,626
<OTHER-SE>                                     203,465
<TOTAL-LIABILITY-AND-EQUITY>                   488,839
<SALES>                                              0
<TOTAL-REVENUES>                                     0
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                             2,196,915
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             103,517
<INCOME-PRETAX>                            (2,300,147)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (2,300,147)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (2,300,147)
<EPS-PRIMARY>                                   (0.26)
<EPS-DILUTED>                                   (0.26)
        

</TABLE>
Exhibit
32.1




CERTIFICATION
PURSUANT TO


18
U.S.C. SECTION 1350,


AS
ADOPTED PURSUANT TO


SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002




In
connection with the Annual Report of Preferred Voice, Inc. (the “Company”) on
Form 10-KSB for the period ending March 31, 2009 as filed with the Securities
and Exchange Commission on the date hereof (the “Report”), I, Mary G. Merritt,
Principal Executive Officer and Principal Financial Officer of the Company,
certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to § 906 of the
Sarbanes-Oxley Act of 2002, that:




(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and




(2)
The information contained in the Report fairly presents, in all material
respects, the financial condition and result of operations of the
Company.




/s/
Mary G. Merritt




Mary G.
Merritt Principal
Executive Officer Principal
Financial Officer June 16,
2009
§ 556.34 Albendazole. ( a ) *Acceptable daily intake (ADI).* The ADI for total residue of albendazole is 5 μg/kg of body weight per day.
( b ) *Tolerances.* The tolerances for albendazole 2-aminosulfone (marker residue) are: ( 1 ) *Cattle.* ( i ) Liver (target tissue): 0.2 ppm.
( ii ) Muscle: 0.05 ppm.
( 2 ) *Sheep.* ( i ) Liver (target tissue): 0.25 ppm.
( ii ) Muscle: 0.05 ppm.
( 3 ) *Goat.* ( i ) Liver (target tissue): 0.25 ppm.
( ii ) [Reserved]
( c ) *Related conditions of use.* See §§ 520.38a and 520.38b of this chapter.
§ 801.35 Voluntary labeling of a device with a unique device identifier. ( a ) The labeler of a device that is not required to bear a unique device identifier (UDI) may voluntarily comply with § 801.20. If a labeler voluntarily includes a UDI for a device, the labeler may voluntarily provide information concerning the device under subpart E of part 830 of this chapter.
( b ) A device may bear both a Universal Product Code (UPC) and a UDI on its label and packages.
[78 FR 58818, Sept. 24, 2013]
§ 524.2098 Selamectin. ( a ) *Specifications.* Each milliliter contains 60 or 120 milligrams (mg) of selamectin.
( b ) *Sponsors.* See Nos. 051072, 051311, 054771, 055529, 061133, and 086117 of this chapter.
( c ) *Conditions of use* — ( 1 ) *Amount.* Administer topically 2.7 mg of selamectin per pound (6 mg per kilogram) of body weight.
( 2 ) *Indications for use.* Kills adult fleas and prevents flea eggs from hatching for 1 month, and it is indicated for the prevention and control of flea infestations (*Ctenocephalides felis*), prevention of heartworm disease caused by *Dirofilaria immitis,* and treatment and control of ear mite (*Otodectes cynotis*) infestations in dogs and cats. Treatment and control of sarcoptic mange (*Sarcoptes scabiei*) and control of tick (*Dermacentor variabilis*) infestations in dogs. Treatment and control of intestinal hookworm (*Ancylostoma tubaeforme*) and roundworm (*Toxocara cati*) infections in cats. For dogs 6 weeks of age and older, and cats 8 weeks of age and older.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[64 FR 37401, July 12, 1999, as amended at 64 FR 48707, Sept. 8, 1999; 65 FR 45282, July 21, 2000; 74 FR 19878, Apr. 30, 2009; 79 FR 10972, Feb. 27, 2014; 86 FR 17064, Apr. 1, 2021; 87 FR 58963, Sept. 29, 2022; 89 FR 14410, Feb. 27, 2024; 89 FR 42360, May 15, 2024]
Exhibit






Amendment No. 1 
to Employment Agreement  

This Amendment No. 1 (“Amendment”) to the EMPLOYMENT AGREEMENT (“Agreement”) is made as of May 4, 2017 (“Amendment Effective Date”) by and between GTT Communications, Inc. (formerly Global Telecom & Technology, Inc.) (“Company”) and Chris McKee (“Executive”).
		
	A.
	Company and Executive have entered into the Agreement on September 7, 2011.


		
	B.
	Company and Executive desire to amend the Agreement in accordance with the terms of this Amendment.


Accordingly, the parties, intending to be legally bound, hereby agree as follows:
		
	1.
	Definitions.  Unless otherwise defined in this Amendment, all capitalized terms shall have the meanings ascribed to such terms in the Agreement.




		
	2.
	Termination – By Company without Cause; By Executive for Good Reason.  Section 7.4 of the Agreement is amended by replacing the current language with the following:




7.4 Termination – By Company without Cause; By Executive for Good Reason.  The Company may terminate the Executive’s employment hereunder at any time, without any Cause, and Executive may resign for Good Reason (as hereinafter defined), without any liability other than to pay to the Executive:  (i) his base salary through the effective date of termination; (ii) the continuation of base salary and health benefits for a period of twelve (12) months after the termination of his employment; (iii) his annual bonus on a pro-rated basis through the effective date of termination as measured for that calendar year; plus (iv) 100% of the target annual bonus the Executive would have been eligible to receive for the twelve (12) month period after the date of termination.   
IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 1 to be effective as of the Amendment Effective Date stated above.
GTT Communications, Inc.
By: ______________________________________        By: ___________________________
Print Name:_______________________________            Name: Chris McKee
Print Title:________________________________